Unleashing T cell anti-tumor immunity: new potential for 5-Nonloxytryptamine as an agent mediating MHC-I upregulation in tumors

被引：0
作者：
Paweł Stachura
Wei Liu
Haifeng C. Xu
Agnès Wlodarczyk
Olivia Stencel
Piyush Pandey
Melina Vogt
Sanil Bhatia
Daniel Picard
Marc Remke
Karl S. Lang
Dieter Häussinger
Bernhard Homey
Philipp A. Lang
Arndt Borkhardt
Aleksandra A. Pandyra
机构：
[1] Heinrich-Heine-University,Department of Molecular Medicine II, Medical Faculty
[2] Heinrich-Heine-University,Department of Pediatric Oncology, Hematology and Clinical Immunology, Medical Faculty, Center of Child and Adolescent Health
[3] Division of Pediatric Neuro-Oncogenomics,Partner Site Essen/Düsseldorf
[4] German Cancer Research Center (DKFZ),Department of Neuropathology, Medical Faculty
[5] German Consortium for Translational Cancer Research (DKTK),Institute of Immunology, Medical Faculty
[6] Heinrich-Heine University,Department of Gastroenterology, Hepatology and Infectious Diseases, Medical Faculty
[7] University of Duisburg-Essen,Department of Dermatology, Medical Faculty
[8] Heinrich-Heine-University,Institute of Clinical Chemistry and Clinical Pharmacology
[9] Heinrich-Heine-University,German Center for Infection Research (DZIF)
[10] University Hospital Bonn,undefined
[11] Partner Site Bonn-Cologne,undefined
来源：
Molecular Cancer | / 22卷
关键词：
CD8; T cells; Immunotherapy; Antigen-presenting machinery; 5-Nonyloxytryptamine (5-NL); Cold tumors; cAMP response element-binding protein (CREB);
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 283 条
[1]  
Shellenberger R(2016)Melanoma screening: A plan for improving early detection Ann Med 48 142-148
[2]  
Nabhan M(2015)Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial Lancet Oncol 16 522-530
[3]  
Kakaraparthi S(2015)Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma N Engl J Med 373 23-34
[4]  
Eggermont AM(2015)Pembrolizumab versus Ipilimumab in Advanced Melanoma N Engl J Med 372 2521-2532
[5]  
Chiarion-Sileni V(2019)Combining Immune Checkpoint Inhibitors: Established and Emerging Targets and Strategies to Improve Outcomes in Melanoma Front Immunol 10 453-722
[6]  
Grob JJ(2018)Economic sustainability of immune-checkpoint inhibitors: the looming threat Nat Rev Clin Oncol 15 721-923
[7]  
Dummer R(2001)Mechanisms contributing to T cell receptor signaling and assembly revealed by the solution structure of an ectodomain fragment of the CD3 epsilon gamma heterodimer Cell 105 913-954
[8]  
Wolchok JD(1999)TCR-Mediated internalization of peptide-MHC complexes acquired by T cells Science 286 952-5056
[9]  
Schmidt H(2015)How Do Cytotoxic Lymphocytes Kill Cancer Cells? Clin Cancer Res 21 5047-854
[10]  
Larkin J(2018)Recent Advances in Targeting CD8 T-Cell Immunity for More Effective Cancer Immunotherapy Front Immunol 9 14-794
12345678910